The University of Virginia (UVA) Cancer Center is directed by Thomas P. Loughran, Jr., MD. He is assisted in this role by the Cancer Center Administration Team and the Senior Leadership. These two groups form the Administrative Core of the UVA Cancer Center. The Cancer Center Administration Team provides the infrastructure and support that enables the University of Virginia matrix Cancer Center to function effectively, efficiently, and cohesively. The Administration Team is led by Dina Gould Halme, PhD (Associate Director for Research Administration) and has staff with expertise in financial management, grants administration, human resources, and philanthropy. The members of the team work with Cancer Center leadership to foster collaborations and support cancer-focused research through infrastructure, Pilot Research Projects, and faculty recruitment. The Senior Leadership team is composed of five Associate Directors: Amy H. Bouton, PhD (Associate Director for Education and Training), Robert Dreicer, MD (Associate Director for Clinical Research), Jay W. Fox, PhD (Associate Director for Laboratory Research Infrastructure), Dina Gould Halme, PhD (Associate Director for Research Administration), and John S. Lazo, PhD (Associate Director for Basic Science). Members of the Senior Leadership each possess a different area of responsibility, perspective, and expertise. Together they form a strong center to the matrix that is the UVA Cancer Center. Dr. Loughran and the Senior Leadership use consensus building in interacting with UVA departments and committees and with the Program Leaders to formulate priorities, develop strategic plans, and allocate resources. They provide recommendations on integrating research between the Programs, discuss collaborations and discoveries within the Programs, assist in oversight of the Shared Resources, and help identify synergies in basic and clinical research and in infrastructure. Collectively, they ensure that the allocation of resources is aligned with the strategic vision of the Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA044579-26
Application #
9209262
Study Section
Special Emphasis Panel (NCI (E3)-A)
Project Start
Project End
Budget Start
2017-02-01
Budget End
2018-01-31
Support Year
26
Fiscal Year
2017
Total Cost
$539,325
Indirect Cost
$197,980
Name
University of Virginia
Department
Type
Domestic Higher Education
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Olmez, Inan; Zhang, Ying; Manigat, Laryssa et al. (2018) Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. Cancer Res 78:4360-4369
Parini, Paolo; Melhuish, Tiffany A; Wotton, David et al. (2018) Overexpression of transforming growth factor ? induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption. Atherosclerosis 275:246-255
Banizs, Anna B; Huang, Tao; Nakamoto, Robert K et al. (2018) Endocytosis Pathways of Endothelial Cell Derived Exosomes. Mol Pharm :
Jia, Deshui; Augert, Arnaud; Kim, Dong-Wook et al. (2018) Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov 8:1422-1437
Manukyan, Arkadi; Kowalczyk, Izabela; Melhuish, Tiffany A et al. (2018) Analysis of transcriptional activity by the Myt1 and Myt1l transcription factors. J Cell Biochem 119:4644-4655
Engelhard, Victor H; Rodriguez, Anthony B; Mauldin, Ileana S et al. (2018) Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. J Immunol 200:432-442
Martins, André L; Walavalkar, Ninad M; Anderson, Warren D et al. (2018) Universal correction of enzymatic sequence bias reveals molecular signatures of protein/DNA interactions. Nucleic Acids Res 46:e9
Michaels, Alex D; Newhook, Timothy E; Adair, Sara J et al. (2018) CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. Clin Cancer Res 24:1415-1425
Shi, Lei; Li, Kang; Guo, Yizhan et al. (2018) Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer. Proc Natl Acad Sci U S A 115:11808-11813
Yang, Jun; LeBlanc, Francis R; Dighe, Shubha A et al. (2018) TRAIL mediates and sustains constitutive NF-?B activation in LGL leukemia. Blood 131:2803-2815

Showing the most recent 10 out of 539 publications